Alexion is to buy rare diseases biotech Syntimmune and its experimental drug for a rare kind of anaemia, in a deal worth up $1.2 billion. The companies have signed a deal where Alexion will pay $ ...

A drug for Wilson disease developed by AstraZeneca's Alexion rare disease unit has cleared a phase 3 trial, setting up regulatory filings in the coming months. The FoCus study of ALXN1840 showed ...

Marc Dunoyer, CEO of AstraZeneca's rare disease group Alexion, told Fierce Biotech at a press conference Thursday morning in London that Alexion “is not immune to the odds of the industry ...

Lauren Drouin is the director of analytical development and the Genomic Medicine Unit at Alexion AstraZeneca Rare Disease. As a dynamic scientist with unique expertise in current research and industry ...

Despite failing in ALS, Alexion, recently acquired by AstraZeneca, brings additional clinical-stage programs for rare diseases. The FDA approved Apellis Pharmaceuticals drug pegcetacoplan ...

The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the addition of eneboparatide (AZP-3601), a Phase 3 ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+ ...

AstraZeneca completed the acquisition of Alexion in 2021 and continues to expand its portfolio by bringing innovative therapies for patients living with rare diseases in India. Alexion’s pioneering ...

The deal brings around $500m of synergies and the technology developed by Alexion complements AstraZeneca’s skills, as it can be applied to more than rare diseases. Meanwhile, Alexion’s ...